Key facts
- It has raised $24.2M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Highlight Capital, Shanghai Healthcare Capital, Zhangjiang Group, Sailing Capital, KCH Capital Management Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for EnnovaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for EnnovaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EnnovaBio
Manufacturer of innovative anti-cancer drugs based in Shanghai, China. The company specialises in targeted therapies, tumour immunotherapy candidates and proprietary platforms for overcoming drug resistance, thereby aiming to improve clinical outcomes and expand treatment options for patients with high medical needs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Website
- ennovabio.com/
- Ownership
- Privately Held (backing)
EnnovaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EnnovaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EnnovaBio in its N-PORT filings yet. We sweep new filings monthly.